 |
Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA) |
|---|---|
| Trade Name | |
| Orphan Indication | Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I |
| USA Market Approval | USA |
| USA Designation Date | 2001-04-11 00:00:00 |
| Sponsor | Novazyme Pharmaceuticals, Inc.;800 Research Parkway, Suite 200;Oklahoma City, Oklahoma, 73104 |
